外显子组测序对伴或不伴胎儿结构异常及死胎的诊断率
该研究回顾性分析344例产前三人家系外显子组测序(trio-ES),其中结构异常胎儿262例、死胎39例、无结构异常胎儿43例。结构异常胎儿诊断率为35.5%,死胎为25.6%,无结构异常胎儿中仅1例(2.3%)检出ORC6复合杂合致病变异。作者认为产前trio-ES可在多种指征中提供分子诊断,但无结构异常胎儿的额外获益与挑战仍需更大规模研究明确。
要点
- 结构异常胎儿trio-ES诊断率为35.5%(93/262),多发与单发异常诊断率相当(p=0.81)。
- 死胎trio-ES诊断率为25.6%(10/39),其中除1例外均伴结构异常,66.6%为多发异常。
- 无结构异常胎儿中仅1/43(2.3%)检出ORC6复合杂合致病变异,关联Meier-Gorlin综合征。
核心结论
- 产前trio-ES可在结构异常胎儿、死胎及无结构异常胎儿等多种指征中提供分子诊断。
- 作者指出,需更大规模研究进一步明确对无结构异常胎儿进行诊断性ES的额外获益与挑战。
研究设计与样本
- 回顾性分析344例产前三人家系外显子组测序(trio-ES)结果。
- 纳入结构异常胎儿262例、死胎39例、无结构异常胎儿43例,其中无结构异常胎儿许多有相关家族史。
- 将符合胎儿表型的基因中致病性变异(P)、可能致病性变异(LP)或倾向致病性的意义未明变异(VUS)归类为诊断性结果。
- 统计分析采用Fisher精确检验。
主要发现
- 结构异常胎儿中93/262(35.5%)获得诊断,多发异常与单发异常的诊断率相当(p=0.81)。
- 死胎中10/39(25.6%)获得分子诊断,其中除1例外均伴结构异常,66.6%为多发异常。
- 无结构异常胎儿中1/43(2.3%)检出ORC6复合杂合致病性变异,关联Meier-Gorlin综合征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出,需更大规模研究进一步明确对无结构异常胎儿进行诊断性ES的额外获益与挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Exome sequencing (ES) benefits the genetic work-up for fetuses with structural anomalies, but data on its utility for fetuses without anomalies and stillbirths is more limited. We report our experience with prenatal ES for all three indications. METHOD: We retrospectively reviewed results from 344 trio-ES performed for fetuses with structural anomalies (N = 262), stillbirths (N = 39), and fetuses without anomalies (N = 43), many of which had a relevant family history. We classified pathogenic variants (P), likely pathogenic variants (LP), or variants of uncertain significance (VUS) favoring pathogenicity in a gene consistent with the fetal phenotype as diagnostic results. We used Fisher's exact test for statistical analysis. RESULTS: Trio-ES provided a diagnosis for 93/262 (35.5%) fetuses with structural anomalies, with comparable yields for multiple and single anomalies (p = 0.81). A molecular diagnosis was made for 10/39 stillbirths (25.6%), of which all but one had structural anomalies, and 66.6% had multiple anomalies. In the absence of structural anomalies, one of 43 fetuses (2.3%) was found to have compound heterozygous pathogenic variants in ORC6 associated with Meier-Gorlin syndrome. CONCLUSION: Prenatal trio-ES yields molecular diagnoses across a spectrum of indications. Larger studies are needed to further define the added benefits and challenges of diagnostic ES for fetuses without anomalies.
引用
- Zemet R, Parobek CM, Adams AD, et al. Diagnostic Yield of Exome Sequencing for Pregnancies With and Without Fetal Anomalies and for Stillbirth. Prenat Diagn. 2025. PMID: 40423626. doi:10.1002/pd.6817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。